We can't find the internet
Attempting to reconnect
18929.1 PFLS-LS
DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease
Zusammenfassung
DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease
Weitere Texte
Abstract
The use of recombinant antibodies as delivery vehicles promises to greatly enhance the therapeutic index of pro-inflammatory and anti-inflammatory cytokines. However, current generation immunocytokines do not elicit cures in vivo whereas combination immunocytokine therapies can. This project aims to develop 'second generation' immunocytokines to capitalize on this observation by combining synergistic cytokine pairs into a single therapeutic molecule
Beteiligte
Catherine Hutchinson
Wirtschaftspartner
catherine.hutchinson@philochem.ch
Philochem AG CHE-113.181.443 Catherine Hutchinson Libernstrasse 3 8112 Otelfingen ZH CH
Dario Neri
Kontaktperson
dario.neri@pharma.ethz.ch
ETH Zürich Inst. of Pharmac. Sciences Dario Neri HCI G496 / Wolfgang-Pauli-Strasse 10 8093 Zürich ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2016-08-31
- Enddatum
- 2017-08-31
- Bewilligte Gesamtkosten
- CHF 55814.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%